Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-053728
Filing Date
2020-11-13
Accepted
2020-11-13 07:20:11
Documents
66
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q prvl-10q_20200930.htm 10-Q 2723427
2 EX-31.1 prvl-ex311_6.htm EX-31.1 18638
3 EX-31.2 prvl-ex312_10.htm EX-31.2 18614
4 EX-32.1 prvl-ex321_8.htm EX-32.1 17903
  Complete submission text file 0001564590-20-053728.txt   7995859

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT prvl-20200930.xml EX-101.INS 1543421
6 XBRL TAXONOMY EXTENSION SCHEMA prvl-20200930.xsd EX-101.SCH 49770
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE prvl-20200930_cal.xml EX-101.CAL 45845
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE prvl-20200930_def.xml EX-101.DEF 206930
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE prvl-20200930_lab.xml EX-101.LAB 430123
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE prvl-20200930_pre.xml EX-101.PRE 338384
Mailing Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016
Business Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016 917-336-9310
Prevail Therapeutics Inc. (Filer) CIK: 0001714798 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38939 | Film No.: 201309155
SIC: 2836 Biological Products, (No Diagnostic Substances)